NeoGenomics Stock Just Turned Its First Profit, Creating an Optimal Entry Point
NeoGenomics (NEO) is a leading cancer genetics diagnostics lab. Its stock recently hit a new 2-year high. Shares are up more than 170% over the past 52 weeks. NEO maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is predominantly bullish, with consensus price targets up to $35 and...
Barchart ·